External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

Key points (machine generated)<ul><li>Opus Genetics is a clinical-stage gene therapy company founded in 2021, focusing on inherited retinal diseases.</li><li>The lead program, OPGx-LCA5, is in a Phase I/II study showing vision improvements, with preliminary pediatric data expected in Q3 2025.</li><li>Opus is also developing OPGx-BEST1 for retinal diseases, with a Phase I/II trial starting in late 2025, and has a speculative risk/reward profile.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Opus Genetics is a clinical-stage gene therapy company founded in 2021, focusing on inherited retinal diseases.The lead program, OPGx-LCA5, is in a Phase I/II study showing vision improvements, with preliminary pediatric data expected in Q3 2025.Opus is also developing OPGx-BEST1 for retinal diseases, with a Phase I/II trial starting in late 2025, and has a speculative risk/reward profile.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Opus Genetics Inc (IRD) - Thursday, Jul 3, 2025

United States

Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs) and other retinal and refractive disorders. Opus Genetics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Opus Genetics (IRD US)

Opus Genetics Inc (IRD) - Thursday, Jul 3, 2025

Opus Genetics, a clinical-stage gene therapy company focused on inherited retinal diseases, is advancing its lead program OPGx-LCA5 in trials, with...

Value Investors Club (VIC)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)